Literature DB >> 6411390

Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease.

I A MacFarlane, D Davies, D Longson, S M Shalet, C G Beardwell.   

Abstract

Twenty-one patients with hyperthyroid Graves' disease were treated with carbimazole 30 mg daily, given as a single dose. Propranolol was also given for the first 3 weeks. All became clinically euthyroid with normal serum thyroxine (T4) levels, usually within 1-3 months. Patients with large goitres and raised serum alkaline phosphatase concentrations took longer to respond. In 19 patients a positive thyroid stimulating hormone (TSH) response to intravenous thyrotrophin releasing hormone (TRH) developed. Carbimazole was stopped soon after (median time of treatment 18 weeks, range 9-41 weeks) and 18 patients have been followed. Seven of these (39%) have remained in remission from hyperthyroidism for more than one year (median 77 weeks). Carbimazole 30 mg once daily is a convenient and effective treatment for hyperthyroid Graves' disease. Many patients will achieve prolonged remissions if treatment is stopped when serum T3 and T4 levels are in the low-normal range, usually 2-4 months after clinical euthyroidism has been reached.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411390     DOI: 10.1111/j.1365-2265.1983.tb00593.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  1 in total

1.  Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.

Authors:  Ali Abbara; Sophie A Clarke; Rosalind Brewster; Alexia Simonnard; Pei Chia Eng; Maria Phylactou; Deborah Papadopoulou; Chioma Izzi-Engbeaya; Amir H Sam; Florian Wernig; Eliza Jonauskyte; Alexander N Comninos; Karim Meeran; Tom W Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-12       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.